Stock Price & Analysis

Could you specify which stock you are referring to as 'A Stock'? This will help provide a more accurate analysis.

Could you please specify the stock you are referring to as 'A Stock'? This will help in providing a precise price prediction for 2025.

The S1 support level for A Stock is $137.75 ,The R1 resistant level for A Stock is $152.31.

As of the end of day on 2025-01-24, the price of A Stock was $151.44.

The target price for A Stock according to analyst rating is 151.33, with the highest price target at 165.00 and the lowest at 135.00. Analysts have a Moderate Buy rating on A Stock overall.

The market cap of A is $43.2B.

Based on the provided data, I'll analyze whether Agilent Technologies (A) is overvalued.

Valuation Metrics Analysis The company's current valuation metrics show:

• P/E ratio: 29.42x (Q4 2024)
• EV/EBITDA: 21.54x (Q4 2024)
• P/S ratio: 5.82x (Q4 2024)
• P/B ratio: 6.30x (Q4 2024)
• Dividend Yield: 0.72%

Technical Analysis

Market Position and Recent Performance The stock is currently trading at $151.44, with a -0.66% change in the last regular trading session . Recent insider activity shows the CEO sold 1,911 shares worth $286,650, representing about 4.6% of their holdings, with no insider purchases reported in the last six months.

Institutional Sentiment Mixed institutional sentiment is evident with:

• 450 institutions increasing positions
• 475 institutions decreasing positions in the latest quarter.

Industry Context The company operates in the medical device sector, which analysts predict will see a rebound in 2025. Agilent is showing "hints of life" with a 10% gain in the early weeks of 2025.

Conclusion Agilent appears overvalued based on:

1. Above-average valuation multiples compared to historical levels
2. Concerning insider selling pattern with no offsetting purchases
3. Mixed institutional sentiment leaning slightly negative
4. Current P/E ratio of 29.42x suggests premium pricing relative to market
5. High EV/EBITDA multiple of 21.54x indicates rich valuation

Agilent Technologies, Inc. is engaged in providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets segment provides application-focused solutions that include instruments, consumables and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics segment includes the genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership and biomolecular analysis businesses. The Agilent CrossLab segment offers services portfolio, which includes repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting and various other custom services to support the laboratory operations.

Could you please specify the stock for which you would like the 2030 price prediction?

A has a total of 18100 employees.